Table 2.
Subgroup analyses of pooled HRs for increased serum CRP and OS in EC
| Subgroup | Number of cohorts | Number of patients | References | HR (95% CI) | Heterogeneity
|
|
|---|---|---|---|---|---|---|
| I2 (%) | P-value | |||||
| Treatment | ||||||
| S | 2 | 441 | 28, 29 | 1.20 (1.05–1.37) | 0.0 | 0.514 |
| S + AT | 5 | 907 | 26, 27, 31, 32, 33 | 2.08 (1.65–2.62) | 55.5 | 0.061 |
| Pathological type | ||||||
| SCC | 2 | 306 | 28, 33 | 1.67 (1.11–2.52) | 0.0 | 0.344 |
| SCC + AC/OT | 5 | 1,122 | 26, 27, 29, 30, 31 | 1.36 (1.20–1.53) | 88.0 | <0.0001 |
| Cut-off level | ||||||
| 5 mg/L | 5 | 1,188 | 19, 20, 23, 24, 27 | 1.38 (1.22–1.56) | 88.6 | <0.0001 |
| 10 mg/L | 3 | 283 | 22, 25, 26 | 1.60 (1.09–2.35) | 0.0 | 0.429 |
Abbreviations: S, surgery; AT, adjuvant therapy; SCC, squamous cell carcinoma; AC, adenocarcinoma; OT, others; HR, hazard ratio; CI, confidence interval; CRP, C-reactive protein; OS, overall survival; EC, esophageal cancer.